PL368539A1 - Kombinacja inhibitora cyklooksygenazy-2 z inhibitorem deacetylazy histonu - Google Patents

Kombinacja inhibitora cyklooksygenazy-2 z inhibitorem deacetylazy histonu

Info

Publication number
PL368539A1
PL368539A1 PL02368539A PL36853902A PL368539A1 PL 368539 A1 PL368539 A1 PL 368539A1 PL 02368539 A PL02368539 A PL 02368539A PL 36853902 A PL36853902 A PL 36853902A PL 368539 A1 PL368539 A1 PL 368539A1
Authority
PL
Poland
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
PL02368539A
Other languages
English (en)
Other versions
PL205853B1 (pl
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL368539A1 publication Critical patent/PL368539A1/pl
Publication of PL205853B1 publication Critical patent/PL205853B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL368539A 2001-11-06 2002-11-05 Kombinacja zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, kompozycja farmaceutyczna zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, zastosowanie tej kombinacji oraz opakowanie handlowe lub produkt handlowy obejmujący inhibitor COX -2 oraz inhibitor deacetylazy histonów PL205853B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17

Publications (2)

Publication Number Publication Date
PL368539A1 true PL368539A1 (pl) 2005-04-04
PL205853B1 PL205853B1 (pl) 2010-06-30

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
PL368539A PL205853B1 (pl) 2001-11-06 2002-11-05 Kombinacja zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, kompozycja farmaceutyczna zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, zastosowanie tej kombinacji oraz opakowanie handlowe lub produkt handlowy obejmujący inhibitor COX -2 oraz inhibitor deacetylazy histonów

Country Status (22)

Country Link
US (3) US7402603B2 (pl)
EP (1) EP1443967B1 (pl)
JP (1) JP4413614B2 (pl)
KR (1) KR100937064B1 (pl)
CN (1) CN100457183C (pl)
AT (1) ATE352319T1 (pl)
AU (1) AU2002351844B2 (pl)
BR (1) BR0213932A (pl)
CA (1) CA2461373A1 (pl)
CY (1) CY1106508T1 (pl)
DE (1) DE60217895T2 (pl)
DK (1) DK1443967T3 (pl)
ES (1) ES2280597T3 (pl)
HU (1) HUP0402370A3 (pl)
IL (2) IL160970A0 (pl)
MX (1) MXPA04004312A (pl)
NO (1) NO20042148L (pl)
NZ (1) NZ544689A (pl)
PL (1) PL205853B1 (pl)
PT (1) PT1443967E (pl)
RU (1) RU2311200C2 (pl)
WO (1) WO2003039599A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
AU2005272389B2 (en) * 2004-08-11 2011-08-04 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminobenzoic acid derivative
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2007146718A2 (en) 2006-06-12 2007-12-21 Novartis Ag Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino] methyl]phenyl]-2e-2-propenamide and starting materials therefor
ME00529B (me) * 2006-06-12 2011-10-10 Novartis Ag Polimorfi n-hidroksi-3-[4-[[[2-(-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida
RU2008151724A (ru) * 2006-06-12 2010-07-20 Новартис АГ (CH) Способ получения солей n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
MX2008016503A (es) * 2006-06-28 2009-06-08 Novartis Ag Uso de inhibidores de hdac para el tratamiento de linfomas.
EP2055692A4 (en) * 2006-08-25 2010-07-07 Asahi Glass Co Ltd PROCESS FOR PREPARING 1,2-DIALKOXY-3-FLUOROBENZOLE
CA2676422C (en) 2007-02-06 2018-10-16 Lixte Biotechnology Holdings, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US20100069458A1 (en) * 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
EA018618B1 (ru) 2007-10-01 2013-09-30 Ликсте Байотекнолоджи, Инк. Ингибиторы hdac
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
KR20140144696A (ko) * 2012-04-16 2014-12-19 도아 에이요 가부시키가이샤 ２환성 화합물
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
JP2005510517A (ja) 2005-04-21
WO2003039599A1 (en) 2003-05-15
CA2461373A1 (en) 2003-05-15
PT1443967E (pt) 2007-04-30
AU2002351844B2 (en) 2006-12-21
DE60217895T2 (de) 2007-07-05
MXPA04004312A (es) 2005-05-16
US20090192211A1 (en) 2009-07-30
KR20050043744A (ko) 2005-05-11
US7402603B2 (en) 2008-07-22
US20050032899A1 (en) 2005-02-10
RU2311200C2 (ru) 2007-11-27
PL205853B1 (pl) 2010-06-30
IL160970A0 (en) 2004-08-31
RU2004117170A (ru) 2005-04-20
BR0213932A (pt) 2004-08-31
HUP0402370A2 (hu) 2005-02-28
CY1106508T1 (el) 2012-01-25
DK1443967T3 (da) 2007-04-16
JP4413614B2 (ja) 2010-02-10
HUP0402370A3 (en) 2008-04-28
NZ544689A (en) 2007-08-31
CN100457183C (zh) 2009-02-04
CN1578674A (zh) 2005-02-09
IL160970A (en) 2010-06-30
KR100937064B1 (ko) 2010-01-15
EP1443967A1 (en) 2004-08-11
ES2280597T3 (es) 2007-09-16
NO20042148L (no) 2004-08-04
ATE352319T1 (de) 2007-02-15
DE60217895D1 (en) 2007-03-15
US20080227845A1 (en) 2008-09-18
EP1443967B1 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
DE60217895D1 (en) Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
JO2434B1 (en) New retinoids to treat emphysema
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EP1461313A4 (en) INHIBITORS OF HUMAN ADAM-10
BR9611897A (pt) Benzofurano carboxamidas e sulfonamidas
AU2003205768A1 (en) Methods and compositions for treating hyperproliferative conditions
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2007128588A3 (de) Glutadon
PL370361A1 (pl) Retynoidowi agoniści I typu alkilomocznika
DE602004019500D1 (en) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
WO2003077874A3 (en) Substituted tetrahydroisoquinoline compounds, methods of making, and their use
PL367707A1 (pl) Kompozycja farmaceutyczna stosowana w leczeniu nowotworów złośliwych zawierająca kombinację bisfosfonianu, inhibitora COX-2 i taksolu
JP2005506371A5 (pl)
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
PT1594456E (pt) Utilização de uma composição contendo óxido de vitamina k1 ou um seu derivado para tratamento e/ou prevenção de lesões dermatológicas em mamíferos
BR0212607A (pt) Agonistas retinóides ii de uréia substituìda
MD2323G2 (ro) Utilizarea bromurii de S-etilizotiouroniu (izoturon) în calitate de preparat uterotonic pentru tratamentul hemoragiilor uterine în cazul miomului uterin
IL156639A0 (en) Phenethanolamine derivatives, methods for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20111105